
Opinion|Videos|October 14, 2023
Role of PI3K Inhibitors in R/R Follicular Lymphoma
Faculty highlight recent changes in treatment guidelines surrounding the use of PI3K inhibitors in follicular lymphoma and discuss the evolving role of these agents in the treatment landscape.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers
2
FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer
3
Lenvatinib Combo Holds Ground Against HER2 ADCs in Endometrial Cancer
4
Teclistamab Combo Earns EU Approval in Relapsed/Refractory Multiple Myeloma
5



















































